Symbols

EVGN

Evogene·NASDAQ

--(--)

EVGN fundamentals

EVGN Q4 2025 Earnings

Evogene (EVGN) released its earnings on Mar 5, 2026: revenue was 314.00K (YoY -80.51%), beat estimates; EPS was -0.61 (YoY -1116.67%), missed estimates.

Revenue / YoY

314.00K

-80.51%

EPS / YoY

-0.61

-1116.67%

Report date

Mar 5, 2026

EVGN Earnings Call Summary for Q4,2025

Strategic Focus: ChemPass AI now sole tech focus, targeting pharma and ag markets with 38B-molecule generative engine
Financial Restructuring: 38% YoY opex reduction to $13.8M, $13M cash on hand
Key Catalysts:
- Upfront payments from pharma deals
- Google-style tech collaborations
- Ag chemical partnerships
Near-Term Cash: $6.4M from Lavie Bio sale, Biomica liquidation proceeds
Pipeline Momentum: 4+ pharma partnerships, Bayer/Corteva collaborations

Earnings

EPS

Revenue

Revenue & Expenses

EVGN has released its 2025 Q4 earnings report, with revenue of 314.00K, reflecting a YoY change of -79.65%, and net profit of -5.35M, showing a YoY change of -106980.00%. The Sankey diagram below clearly presents EVGN's revenue sources and cost distribution.

Key Indicators

Evogene (EVGN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Evogene (EVGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Evogene (EVGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Evogene (EVGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown